Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 39.84
+0.54 (1.37%)
May 6, 2026, 3:00 PM CST
SHA:603392 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -388.47 | -398.27 | 106.24 | 1,248 | 4,736 | 2,021 |
Depreciation & Amortization | 313.67 | 313.67 | 300.65 | 231.51 | 151.9 | 105.28 |
Other Amortization | 53.78 | 53.78 | 17.59 | 60.55 | 6.63 | 5.03 |
Loss (Gain) From Sale of Assets | -60.23 | -60.23 | -7.92 | -0.22 | -0.06 | 0.72 |
Asset Writedown & Restructuring Costs | 2.19 | 2.19 | 0.53 | 224.01 | 2.8 | 0.25 |
Loss (Gain) From Sale of Investments | -114.51 | -114.51 | -146.34 | -123.56 | -46.09 | -11.25 |
Provision & Write-off of Bad Debts | 23.08 | 23.08 | 11.89 | -23.27 | 90.61 | 83.95 |
Other Operating Activities | 48.95 | 204.82 | 86.71 | 199.37 | 129.61 | 96.86 |
Change in Accounts Receivable | 398.16 | 398.16 | 940.33 | 984.81 | -1,778 | -1,707 |
Change in Inventory | -40.54 | -40.54 | -58.18 | -218.34 | -296.47 | -222.97 |
Change in Accounts Payable | -183.4 | -183.4 | -805.75 | -935.62 | 1,116 | 1,322 |
Change in Other Net Operating Assets | -14.15 | -14.15 | -5.28 | - | - | -0 |
Operating Cash Flow | -56.32 | 89.75 | 355.08 | 1,538 | 4,133 | 1,682 |
Operating Cash Flow Growth | - | -74.72% | -76.91% | -62.79% | 145.70% | 259.23% |
Capital Expenditures | -750.09 | -805.16 | -887.35 | -1,160 | -929.91 | -1,048 |
Sale of Property, Plant & Equipment | 210.68 | 210.73 | 16.06 | 0.72 | 0.89 | 8.19 |
Cash Acquisitions | - | - | - | -0.71 | - | - |
Investment in Securities | 1,566 | -281.81 | -794.66 | -960.3 | -2,589 | 14.39 |
Other Investing Activities | -1,064 | 117.24 | 162.59 | 66.23 | 3.9 | 11.11 |
Investing Cash Flow | -37.22 | -759.01 | -1,503 | -2,054 | -3,514 | -1,014 |
Long-Term Debt Issued | - | 343.56 | 231.24 | 186.44 | 351.6 | 240.35 |
Long-Term Debt Repaid | - | -339.89 | -272.81 | -170.57 | -352.46 | -92.06 |
Net Debt Issued (Repaid) | 29.68 | 3.67 | -41.57 | 15.87 | -0.86 | 148.29 |
Issuance of Common Stock | - | - | 78.21 | 54 | 3,461 | 10 |
Repurchase of Common Stock | - | - | -238.44 | -15.65 | -200.17 | - |
Common Dividends Paid | -1.92 | -2.28 | -410.94 | -907.47 | -127.49 | -112.74 |
Other Financing Activities | -1.27 | -0.92 | - | -40 | -5.68 | 7.23 |
Financing Cash Flow | 26.48 | 0.47 | -612.74 | -893.26 | 3,127 | 52.79 |
Foreign Exchange Rate Adjustments | -25.63 | -13.27 | 4.38 | 7.62 | 26.26 | -8.75 |
Net Cash Flow | -92.69 | -682.05 | -1,757 | -1,402 | 3,772 | 711.88 |
Free Cash Flow | -806.4 | -715.41 | -532.27 | 378.15 | 3,203 | 634.16 |
Free Cash Flow Growth | - | - | - | -88.19% | 405.03% | 715.43% |
Free Cash Flow Margin | -41.53% | -39.33% | -23.71% | 6.86% | 28.63% | 11.03% |
Free Cash Flow Per Share | -0.61 | -0.56 | -0.40 | 0.30 | 2.56 | 0.52 |
Cash Income Tax Paid | 181.35 | 163.2 | 114.16 | 537.3 | 1,164 | 295.76 |
Levered Free Cash Flow | -537.49 | -589.82 | -22.12 | -308.83 | 1,738 | -4.04 |
Unlevered Free Cash Flow | -533.74 | -585.78 | -16.92 | -304.55 | 1,743 | -0.48 |
Change in Working Capital | 65.23 | 65.23 | -14.26 | -278.25 | -938.6 | -620.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.